LogicBio Therapeutics

$9.06
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.77 (+9.29%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell LOGC and other stocks, options, and ETFs commission-free!

About LOGC

LogicBio Therapeutics, Inc. Common Stock, also called LogicBio Therapeutics, is a genome editing company, which engages in developing medicines to treat rare diseases in patients with significant unmet medical need. It focuses on the commercialization of specific genome editing and integration of the therapeutic transgene. The company was founded by Mark A. Kay, Leszek Lisowski, and Adi Barzel in August 2014 and is headquartered in Cambridge, MA. The listed name for LOGC is LogicBio Therapeutics, Inc. Common Stock.

CEO
Frédéric Chéreau
Employees
41
Headquarters
Lexington, Massachusetts
Founded
2014
Market Cap
270.88M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
163.49K
High Today
$9.06
Low Today
$8.50
Open Price
$8.80
Volume
209.47K
52 Week High
$10.00
52 Week Low
$3.05

LOGC Earnings

-$0.51
-$0.34
-$0.17
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 15

You May Also Like

LOKB+
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure